Strategic partner: AstraZeneca
11 November 2019Scientists at AstraZeneca, a global biopharmaceutical company, have been working with Cambridge University for more than two decades. What are the secrets of their success?
University of Cambridge breaks its early stage investment record for third consecutive year
27 January 2016For the third consecutive year, the University of Cambridge has broken its early stage investment record, approving 13 seed fund investments for a total of £3.8 million, an increase on the £3.2 million invested in 2013-14.
Topping out for West Cambridge building
10 July 2014Progress on the new home for the Department of Chemical Engineering and Biotechnology (CEB) has been celebrated with a traditional topping-out ceremony.
Clearing the BAR to oral vaccines
10 June 2013A new technology under development by an academic–industry partnership protects oral vaccines from destruction by the digestive system.
Single component biology is past; bioengineering has begun
01 October 2008Professor Nigel Slater, from the Department of Chemical Engineering and Biotechnology, describes how the influx of ideas and principles from non-biological disciplines is shaping a new biology.
